General Sarcoma


Chemotherapy Before Surgery Improves Treatment of Sarcoma (November 7, 2016)

For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival.... Continue Reading

YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma (February 4, 2015)

The U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YONDELIS® (trabectedin) to treat patients with advanced soft tissue sarcoma (STS), including... Continue Reading

Torisel Improves Event-Free Survival in Rhabdomyosarcoma Patients (June 27, 2014)

In a study presented at the 2014 American Society of Clinical Oncology® meeting in Chicago, researchers reported that Torisel® (temsirolimus) added to a chemotherapy regimen improved event-free survival... Continue Reading

Regorafenib May Expand GIST Treatment Options (June 13, 2012)

Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical... Continue Reading

Votrient Approved for the Treatment of Sarcoma (May 7, 2012)

The U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. It is the first... Continue Reading

Longer Treatment with Gleevec Effective Against Gastrointestinal Stromal Tumors (GIST) (April 9, 2012)

In a Phase III clinical trial, three years of adjuvant (post-surgery) treatment with Gleevec® (imatinib) resulted in better survival than one year of adjuvant treatment among patients with high-risk gastrointestinal... Continue Reading

Genetic Change Linked with Rhabdomyosarcoma Survival (April 4, 2012)

For children with rhabdomyosarcoma, a test for a specific genetic change could eventually improve risk estimates and treatment decisions. These results were published in the Journal of Clinical Oncology. Rhabdomyosarcoma... Continue Reading

FDA Updates Use of Gleevec for Gastrointestinal Stromal Tumors (February 29, 2012)

In changes approved by the US Food and Drug Administration (FDA), the prescribing information for Gleevec® (imatinib) now notes that three years of adjuvant (post-surgery) treatment results in better... Continue Reading

Halaven Promising in Soft-Tissue Sarcoma (September 26, 2011)

The chemotherapy drug Halaven™ (eribulin mesylate) may be a promising therapy for certain types of soft-tissue sarcoma. These findings were recently reported in the Lancet Oncology. Halaven—which... Continue Reading

Stay on Top of Your Family History of Cancer (July 15, 2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s... Continue Reading

Kepivance Effective in Managing Mucositis in Patients Undergoing Multiple Cycles of Chemotherapy (October 5, 2010)

A single dose of Kepivance® (palifermin) prior to each cycle of chemotherapy in sarcoma patients may substantially reduce the likelihood of moderate to severe mucositis. These findings from a randomized,... Continue Reading

High-risk Soft Tissue Sarcoma Patients Benefit from Targeted Heat Therapy Combined with Chemotherapy (May 7, 2010)

A technique called regional hyperthermia (RHT) makes chemotherapy more effective and improves outcomes in patients with localized, high-risk soft tissue sarcoma, according to the results of a study recently... Continue Reading

Targeted Heat Therapy Improves Outcomes for Soft Tissue Sarcoma (September 30, 2009)

A new technique called regional hyperthermia (RHT) makes chemotherapy more effective and improves outcomes in patients with soft tissue sarcoma, according to the results of a study presented on September... Continue Reading

Differences in IMRT Radiation Doses May Complicate Study Results in Sarcomas (April 9, 2008)

Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in sarcomas difficult to interpret.... Continue Reading

PET Scan More Accurate Predictor of Treatment Response for Soft Tissue Sarcomas (February 8, 2008)

PET Scan More Accurate Predictor of Treatment Response for Soft Tissue Sarcomas Positron emission tomography (PET) scans were found to be significantly more accurate than standard methods in judging response... Continue Reading

Sutent® Linked with Heart Problems (January 8, 2008)

Sutent® Linked with Heart Problems According to the results of a study published in the Lancet, treatment with Sutent® (sunitinib) was linked with the development of heart problems in some patients with... Continue Reading

Update in the Management of Gastrointestinal Stromal Tumors (GIST): A Report from ASCO 2007 (October 12, 2007)

Update in the Management of Gastrointestinal Stromal Tumors (GIST): A Report from ASCO 2007 Gastrointestinal stromal tumors (GIST) and their management have become an important focus for clinical research.... Continue Reading

Survival for Soft Tissue Sarcoma Patients Improved at High-volume Centers (June 6, 2007)

Survival for Soft Tissue Sarcoma Patients Improved at High-volume Centers According to an article recently published in Annals of Surgery, survival and physical function for patients with soft tissue sarcoma... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS